Cocaine Addiction
7
Pipeline Programs
3
Companies
3
Clinical Trials
4
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
1
4
Early DiscoveryClinical DevelopmentMarket
On Market (4)
Approved therapies currently available
U
SABRILApproved
vigabatrin
Unknown CompanyAnti-epileptic Agent [EPC]oral2009
U
VIGADRONEApproved
vigabatrin
Unknown CompanyAnti-epileptic Agent [EPC]oral2018
U
VIGAFYDEApproved
vigabatrin
Unknown CompanyAnti-epileptic Agent [EPC]oral2024
U
VIGPODERApproved
vigabatrin
Unknown CompanyAnti-epileptic Agent [EPC]oral2022
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Mission TherapeuticsModafinil and PET
Catalyst PharmaceuticalsVigabatrin
TevaTV-1380 150 mg
Clinical Trials (3)
Total enrollment: 237 patients across 3 trials
Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction
Start: Apr 2009Est. completion: Jan 201329 patients
Phase 3Completed
Vigabatrin for the Treatment of Cocaine Dependency
Start: Jan 2011Est. completion: Dec 2012
Phase 2/3Completed
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
Start: Jun 2013Est. completion: Oct 2014208 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space